EXELON

LOE Approaching

rivastigmine

NDATRANSDERMALFILM, EXTENDED RELEASE
Approved
Jul 2007
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20

Mechanism of Action

Cholinesterase Inhibitors

Pharmacologic Class:

Cholinesterase Inhibitor

Clinical Trials (5)

NCT02989402Phase 4Completed

A Phase IV Study to Evaluate Safety, Tolerability and Effectiveness of Rivastigmine Patch 15cm2 in Patients With Severe Dementia of the Alzheimer's Type.

Started Dec 2018
100 enrolled
Alzheimer's Disease
NCT02703636Phase 4Completed

NextStep:Study to Evaluate Safety,Efficacy & Tolerability of Rivastigmine Patch in Mild to Moderate Alzheimer's Patients.

Started May 2016
118 enrolled
Mild to Moderate Alzheimer's Disease
NCT01948791Phase 4Completed

16w Interventional Study on Titration and Dose/Efficacy Assessment of Exelon in Chinese Alzheimer's Disease Patients

Started Aug 2014
222 enrolled
Alzheimer's Disease
NCT02063269N/AUnknown

Brain Changes by Rivastigmine According to Butyrylcholinesterase Alleles

Started Feb 2014
70 enrolled
Alzheimer's Disease
NCT01585272Phase 4Completed

Tolerability of Rivastigmine Before and After Switching From Oral Formulation to Transdermal Patch in Alzheimer's Dementia

Started Aug 2012
121 enrolled
Alzheimer's Dementia